
Novus Therapeutics (NVUS) P/E Ratio
P/E Ratio as of Dec 4, 2025: -1.32
Average-1.62
Median-1.35
Minimum-3.22
Maximum-1.16
-1.32
2.06 (60.95%)past month
The P/E ratio for Novus Therapeutics (NVUS) is -1.32 as of Dec 4, 2025. This represents a decrease of -8.33% compared to its 12-month average P/E ratio of -1.44. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Novus Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Novus Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Novus Therapeutics to industry peers.
Novus Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Novus Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Novus Therapeutics to industry peers.
Novus Therapeutics (NVUS) P/E Ratio Insights
See Novus Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Novus Therapeutics (NVUS)
Order type
Buy in
Order amount
Est. shares
0 shares
Novus Therapeutics (NVUS) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $1.53 | -1.27 |
| Nov 3, 2025 | $4.36 | -3.38 |
| Oct 1, 2025 | $2.66 | -2.06 |
| Sep 2, 2025 | $2.55 | -1.97 |
| Aug 1, 2025 | $3.38 | -1.53 |
| Jul 1, 2025 | $2.79 | -1.26 |
| Jun 2, 2025 | $3.06 | -1.39 |
| May 1, 2025 | $3.28 | -1.13 |
| Apr 1, 2025 | $3.22 | -1.11 |
| Mar 3, 2025 | $4.005 | -0.70 |
| Feb 3, 2025 | $4.46 | -0.78 |
| Jan 2, 2025 | $4.29 | -0.75 |
Novus Therapeutics (NVUS) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -1.32 | +83.33% |
| 2024 | -0.72 | +132.26% |
| 2023 | -0.31 | -63.53% |
| 2022 | -0.85 | -54.79% |
| 2021 | -1.88 | +108.89% |
| 2020 | -0.90 | — |
FAQs About Novus Therapeutics (NVUS) P/E ratio
The latest P/E ratio of Novus Therapeutics (NVUS) is -1.32, as of Dec 4, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Novus Therapeutics’s last 12-month average P/E ratio is -1.44, compared to its current P/E ratio of -1.32. This reflects a decrease of -8.33%.
Novus Therapeutics’s current P/E ratio of -1.32 is lower than its last 12-month average P/E of -1.44. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Novus Therapeutics’s average P/E ratio over the last 3 years is -0.75. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Novus Therapeutics’s average P/E ratio over the last 5 years is -0.99. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.